3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Recruiting
1
Sponsor Class
OTHER
1
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gynecologic
1
Conditions
Breast Neoplasms
3
Triple Negative Breast Neoplasms
2
Neoplasm Metastasis
2
Recurrence
1
Ovarian Neoplasms
1
Neoplasms
1
Leukemia, Myeloid, Acute
1
Fallopian Tube Neoplasms
1
Carcinoma, Ovarian Epithelial
1
Carcinoma, Non-Small-Cell Lung
1
Interventions
Paclitaxel
32
Carboplatin
23
liposomal doxorubicin
14
pembrolizumab
12
Topotecan
10
Bevacizumab
10
Gemcitabine
9
mirvetuximab soravtansine
8
olaparib
6
Cisplatin
6
1-dodecylpyridoxal
6
rucaparib
5
Nivolumab
5
Cyclophosphamide
5
oregovomab
4
farletuzumab
3
catumaxomab
3
Standard of Care
3
Irinotecan
3
Fulvestrant
3
CCV-AV protocol
3
talazoparib
2
sacituzumab govitecan
2
ribociclib
2
phenoxodiol
2
pegfilgrastim
2
pazopanib
2
palbociclib
2
niraparib
2
fludarabine
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
INDUSTRY
×
Carcinoma, Ovarian Epithelial
×
Palliative Care
×
Clear all
NCT07617753
2026-06-01
DUAL-OV-CAR-NK
Beijing Biotech
Phase 1/2
Recruiting
36 enrolled